RPCEC00000037已完成2 期
Clinical trial of Dermatophagoides pteronyssinus allergenic extract (VALERGEN-DP), for subcutaneous therapeutic use in asthmatic adults sensitive to this allergen.
ational Biopreparations Center (BIOCEN)0 个研究点开始时间: 2010年12月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 16 years 至 45 years（—）
- 性别
- All
入选标准
- •1. Asthmatic allergic patients with positive responses during the preliminary survey in the following aspects: family and personal history of atopy, clinical symptoms only triggered when exposed to dust at home, mainly indoors, when getting up in the morning or going to bed at night. 2. Skin test positive to D. pteronyssinus allergenic extract, 20,000 BU/ml VALERGEN-DP. The response to the allergen under study is predominant when compared to that obtained with other mites. 3. Patients included in the study will be patients clinically diagnosed as extrinsic asthmatics who, in according to the clinical-therapeutic identification booklet, are classified as mild or moderate persistent patients in keeping with the International Agreement on Asthma Diagnosis and Treatment. 4. Age between 16 and 45 years. 5. Any sex and race. 6. Patients expressing their consent in writing to participate in our trial.
排除标准
- •1. Patients not giving their consent in writing (Model 6) to participate in our trial. 2. Patients on allergenic extract immunotherapy during the two preceding years. 3. Patients classified as intermittent or severe persistent asthmatics after being interviewed. 4. Patients with a diagnosed autoimmune disease of any kind. 5. Generalized severe eczema. 6. Patients with diagnosed tumoral disease. 7. Patients on betablocker treatment. 8. Patients with psychiatric disorders. 9. Patients not cooperating with treatment. 10. Patients who, at least one year before the study, needed immunostimulant or immunosuppressor treatment (no corticosteroids), including interferon and cyclosporine A. 11. Pregnancy and breastfeeding. 12. Adrenalin-contraindicated patients (high blood pressure). 13. Patients who, at least one year before the study, were under non-conventional treatments such as: Vimang, Aloe, ozone, banana capsules.
研究者
相似试验
已完成
2 期
Efficacy of VALERGEN-DP sublingual vaccine in asthmatic adults.AsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessBronchial asthmaRPCEC00000034ational Biopreparations Center (BIOCEN)
已完成
2 期
Efficacy of VALERGEN-DP subcutaneous vaccine in asthmatic adultsBronchial asthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessAsthmaRPCEC00000027ational Biopreparations Center (BIOCEN)
已完成
2 期
Evidence of the clinical efficacy of VALERGEN-DS vaccine in asthmatics.Bronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessAsthmaBronchial asthmaRPCEC00000032ational Biopreparations Center (BIOCEN)
已完成
2 期
Efficacy of VALERGEN-DS sublingual vaccine in asthmatic adultsBronchial asthma.Bronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessAsthmaRPCEC00000030ational Biopreparations Center (BIOCEN)
已完成
3 期
Efficacy of VALERGEN-DS subcutaneous vaccine in asthmatic adults.Bronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessAsthmaBronchial asthmaRPCEC00000028ational Biopreparations Center (BIOCEN)